



P2Y₆ Receptors Regulate CXCL10 Expression and Secretion in Mouse Intestinal Epithelial Cells

Mabrouka Salem^{1,2}, Alain Tremblay², Julie Pelletier², Bernard Robaye³ and Jean Sévigny^{1,2*}

¹ Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine, Université Laval, Québec City, QC, Canada, ² Centre de Recherche du CHU de Québec – Université Laval, Québec City, QC, Canada, ³ Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Gosselies, Belgium

OPEN ACCESS

Edited by:

Kenneth A. Jacobson,
National Institutes of Health (NIH),
United States

Reviewed by:

Fernando Ochoa-Cortes,
Universidad Autónoma de San Luis
Potosí, Mexico
Markus Neurath,
Universitätsklinikum Erlangen,
Germany

Robin Mark Howard Rumney,
University of Portsmouth,
United Kingdom

*Correspondence:

Jean Sévigny
jean.sevigny@crchudequebec.
ulaval.ca

Specialty section:

This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology

Received: 16 November 2017

Accepted: 13 February 2018

Published: 28 February 2018

Citation:

Salem M, Tremblay A, Pelletier J,
Robaye B and Sévigny J (2018) P2Y₆
Receptors Regulate CXCL10
Expression and Secretion in Mouse
Intestinal Epithelial Cells.
Front. Pharmacol. 9:149.
doi: 10.3389/fphar.2018.00149

In this study, we investigated the role of extracellular nucleotides in chemokine (KC, MIP-2, MCP-1, and CXCL10) expression and secretion by murine primary intestinal epithelial cells (IECs) with a focus on P2Y₆ receptors. qRT-PCR experiments showed that P2Y₆ was the dominant nucleotide receptor expressed in mouse IEC. In addition, the P2Y₆ ligand UDP induced expression and secretion of CXCL10. For the other studies, we took advantage of mice deficient in P2Y₆ (*P2ry6*^{-/-}). Similar expression levels of P2Y₁, P2Y₂, P2X₂, P2X₄, and A_{2A} were detected in *P2ry6*^{-/-} and WT IEC. Agonists of TLR3 (poly(I:C)), TLR4 (LPS), P2Y₁, and P2Y₂ increased the expression and secretion of CXCL10 more prominently in *P2ry6*^{-/-} IEC than in WT IEC. CXCL10 expression and secretion induced by poly(I:C) in both *P2ry6*^{-/-} and WT IEC were inhibited by general P2 antagonists (suramin and Reactive-Blue-2), by apyrase, and by specific antagonists of P2Y₁, P2Y₂, P2Y₆ (only in WT), and P2X₄. Neither adenosine nor an A_{2A} antagonist had an effect on CXCL10 expression and secretion. Macrophage chemotaxis was induced by the supernatant of poly(I:C)-treated IEC which was consistent with the level of CXCL10 secreted. Finally, the non-nucleotide agonist FGF2 induced MMP9 mRNA expression also at a higher level in *P2ry6*^{-/-} IEC than in WT IEC. In conclusion, extracellular nucleotides regulate CXCL10 expression and secretion by IEC. In the absence of P2Y₆, these effects are modulated by other P2 receptors also present on IEC. These data suggest that the presence of P2Y₆ regulates chemokine secretion and may also regulate IEC homeostasis.

Keywords: intestinal epithelial cells (IEC), P2Y₆, CXCL10, TLR, nucleotides

INTRODUCTION

Dysregulation of immune response is an important contributor to inflammatory bowel diseases in which the epithelium plays central functions. The intestine is bordered by intestinal epithelial cells (IECs) that represent the first line of defense against environmental pathogens. In addition to acting as a physical barrier to prevent passage of luminal contents, IECs are crucial for maintaining intestinal homeostasis. For example, IECs express a wide range of pattern-recognition receptors (PRRs), including Toll-like receptors (TLRs) that are activated by pathogen-associated molecular patterns (PAMPs) (Qureshi and Medzhitov, 2003; Medzhitov, 2007). The activation of these receptors results in the activation of innate immune responses, inducing the expression

of pro-inflammatory cytokines, chemokines, and antimicrobial peptides (Fritz et al., 2006; Artis, 2008).

Once injured, or upon mechanical stimulation, epithelial cells such as bronchial and IECs release danger signals such as nucleotides which include adenosine triphosphate (ATP), uridine triphosphate (UTP), and their derivatives (Hazama et al., 1999; Braunstein et al., 2001; Vitiello et al., 2012). These molecules can alert the immune system by initiating tissue inflammation via the activation of plasma membrane P2 receptors (Lazarowski et al., 2003; Kukulski et al., 2011). Based on their structure and distinct signal-transduction mechanism, P2 receptors are divided into P2X (P2X₁₋₇) and P2Y (P2Y_{1,2,4,6,11,12,13,14}) subfamilies (Abbracchio et al., 2006). Among the P2YR receptor subtypes, P2Y₆ is known as a pro-inflammatory receptor which is specifically activated by UDP in human and by UTP and UDP in mouse (Kauffenstein et al., 2010). Several reports suggested an important role of P2Y₆ receptors in modulating cellular responses to inflammation. P2Y₆ participates in the regulation of TLR1/2-induced IL-8 secretion from monocytes and, as a consequence, in neutrophil migration (Ben Yebdri et al., 2009). In microglia and astrocytes, P2Y₆ activation results in the regulation of CCL2 expression (Kim et al., 2011). Moreover, its activation results in the amplification of chemokine secretion induced by lipopolysaccharide (LPS) in the monocytic cell line (THP-1) and in human and mouse monocytes/macrophages (Warny et al., 2001; Kukulski et al., 2007; Bar et al., 2008).

In the context of the gastrointestinal tract, P2Y₆ receptors were reported to be strongly expressed by colonic epithelial cells in biopsies from patients with inflammatory bowel disease (Grbic et al., 2008). It was also shown that colonic epithelial cell lines challenged by TNF stimulation, to mimic an inflammatory stress, release UDP which activates P2Y₆ receptor and mediates production of CXCL8 (Grbic et al., 2008). There are also some reports that show increase of chemokine expression in IEC lines upon bacterial infection or stimulation with TNF- α or IL-1 α (Jung et al., 1995; Yang et al., 1997) in which it is not excluded that P2Y₆ may participate.

Other studies suggest that CXCL10 has a strong association with inflammatory diseases and particularly with intestinal inflammation (Laragione et al., 2011; Bondar et al., 2014). In humans, CXCL10 is constitutively expressed by colonic epithelial cells (Dwinell et al., 2001) and it is permanently over-expressed in patients with ulcerative colitis (UC) and Crohn's disease (CD) (Ugucioni et al., 1999; Ostvik et al., 2013; Singh et al., 2016). CXCL10 is a chemoattractant for activated T cells and monocytes (Suzuki et al., 2007; Zhao et al., 2017). It was shown that CXCL10, by binding to CXCR3 receptors, is responsible for Th1 cell differentiation and trafficking into both, the epithelium and the lamina propria of inflamed colons (Ugucioni et al., 1999; Suzuki et al., 2007). Additionally, CXCL10 is responsible for macrophage chemotaxis in murine models of inflammation: non-alcoholic steatohepatitis and puromycin aminonucleoside nephrosis (Petrovic-Djergovic et al., 2015; Tomita et al., 2016).

Giving the fact that the expression of P2Y₆ receptor by IEC is increased in inflammatory condition and in biopsies of patients with intestinal inflammation and that it contributes to chemokine release such as CXCL8, we hypothesized that P2Y₆ receptor plays

a role in the secretion of chemokines by IEC and in immune cell migration to the epithelium. We addressed this hypothesis here with primary IEC cultures from mice deficient in the expression of P2Y₆ receptor. We observed that extracellular nucleotides, via the activation of P2Y₆ and also of other P2 receptors, regulate the expression and secretion of CXCL10. In addition, our results also show that IEC deficient for P2Y₆ respond more vigorously to stimulation with several ligands activating other nucleotide receptors as well as a non-nucleotide receptor. In other words, these data suggest that P2Y₆ activation not only activates the synthesis and release of a chemokine but that the presence of P2Y₆ also maintains a proper state of activation of these cells, preventing them from overstimulation by several stimuli.

MATERIALS AND METHODS

Reagents and Chemicals

Suramin and Reactive-Blue-2 (RB-2) were obtained from MP Biomedical (Santa Ana, CA, United States). DMEM/F12, advanced DMEM/F12, HEPES, L-glutamine, penicillin, streptomycin, FBS, Dulbecco's PBS, apyrase, formyl-methionine-leucyl-phenylalanine (FMLP), LPSs, adenosine 5'-triphosphate (ATP), adenosine 5'-diphosphate (ADP), uridine 5'-triphosphate (UTP), uridine 5'-diphosphate (UDP), adenosine, Zm 241385, and fibroblast growth factor 2 (FGF2) were purchased from Sigma-Aldrich (Oakville, ON, Canada). Collagenase type I, SuperScript III, gentamicin, B-27 and N-2 supplements, polyinosinic-polycytidylic acid [poly(I:C)], EDTA, and TRIzol were obtained from Invitrogen (Carlsbad, CA, United States). Collagen type I was purchased from BD Bioscience (San Jose, CA, United States). Y-27632, mrEGF, Wnt-3a, and R-spondin were purchased from R&D Systems (Minneapolis, MN, United States). Noggin and M-CSF were purchased from PeproTech (QC, Canada). SYBR Green and DNaseI were from Roche Diagnostics (Indianapolis, IN, United States). Flagellin was obtained from InvivoGen (San Diego, CA, United States). Oligo(dt)18 was obtained from Fisher Scientific (Ottawa, ON, Canada). MRS 2500, MRS 2179, MRS 2578, AR-C 118925XX, PSB 1114, and 5-BDBD were purchased from Tocris Bioscience (Minneapolis, MN, United States).

Animals

All experiments were conducted according to the Canadian Council on Animal Care and the protocols were approved by the Animal Care Committee of Laval University. Adult male C57Bl/6 mice 8–12 weeks (Charles River, Pointe-Claire, QC, Canada) were used as control. *P2ry6*^{-/-} mice were bred at our animal facility in CHUL. Previously to the experiments presented in this paper, P2Y₆-deficient mice obtained from B. Robaye (Université Libre de Bruxelles, Belgium) (Bar et al., 2008) were backcrossed 10 times with C57Bl/6 mice from Charles River. A few backcrosses with WT females were performed to ascertain that the mitochondrial DNA is the same in mutant and control mice. Animals were maintained in a specific pathogen-free environment in a temperature-controlled room (21°C) on a 12-h/12-h light and dark cycle and given unrestricted access to

standard diet and tap water. Mice were allowed to acclimate to these conditions for at least 7 days before experimentation.

Intestinal Epithelial Cell Isolation

Primary IECs were isolated from WT and *P2ry6*^{-/-} mice according to Moon et al. (2014) and Graves et al. (2014) with minor modifications as detailed below. Briefly, the longitudinal muscle layer was removed and the colonic tissue was washed with ice-cold Mg²⁺ and Ca²⁺ free salt solution (PBS). Obtained tissue was incubated with 75 U ml⁻¹ collagenase type V for 30 min and the reaction was stopped with Dulbecco's modified Eagles medium (DMEM/F12) containing 10% v/v fetal bovine serum (FBS), L-glutamine, HEPES, N-2 supplement, B-27 supplement, and antibiotics as before. The digestion mixture was filtered through a 70- μ m mesh and the effluent containing crypts was centrifuged twice at 50 \times g for 5 min at 4°C. The remaining pellet comprising isolated intestinal crypts was suspended in complete growth media DMEM/F12 advance containing 50 ng/ml mrEGF, 1 μ g/ml R-spondin, 100 ng/ml noggin, and 5 ng/ml Wnt-3a in the presence of 10 μ M Y-27632 as an anoikis inhibitor. The suspended crypts were then plated in a 24-well plate coated with type I collagen at a density of 1000 crypts/well. Cells were incubated at 37°C in a 5% CO₂ incubator. The media was replaced 48 h later without Y-27632 and the epithelial cells from the crypts were allowed to grow to confluence for 2 days to obtain a monolayer of differentiated IEC. The cells were either collected for qPCR or stimulated as detailed below.

IEC Stimulation

Intestinal epithelial cells were stimulated for 5 (for qPCR experiments) or 24 h (for ELISA experiments) with the ultrapure TLR agonists poly(I:C) [TLR3] (10 μ g/ml), LPS [TLR4] (100 ng/ml), flagellin [TLR5] (100 ng/ml), or with the nucleotide ATP, ADP, UTP, UDP, or adenosine all at the concentration of 100 μ M. In some experiments, IEC culture was stimulated with poly(I:C) in the presence of general P2 receptor blockers added 20 min before stimulation, suramin (100 μ M), RB-2 (100 μ M), apyrase (2 U/ml), or in the presence of specific antagonist of P2Y₁, P2Y₂, P2Y₆, P2X₄, or A_{2A} receptor (as described in the legend of the figures).

Quantitative Real-Time PCR (qRT-PCR) and ELISA

RNA extraction, cDNA synthesis, and quantification were performed as described previously with some modifications (Bahrami et al., 2014). Briefly, total RNA from stimulated or unstimulated IEC monolayer was extracted with TRIzol then quantified with a Quant-iT RNA BR Assay Kit and Qubit Fluorometer. The cDNA was synthesized with SuperScript III from 1 μ g of total RNA with oligo (dT)₁₈ as the primer, according to the instructions of the manufacturer (Invitrogen, Carlsbad, CA, United States). Primers specific for the differentiation marker villin, for the ectonucleotidases, and for P2X, P2Y, and P1 receptors were either designed by us and synthesized by Invitrogen (Carlsbad, CA, United States) or purchased from Qiagen (Toronto, ON, Canada), as detailed in **Table 1**. SYBR

Green Supermix was used for qRT-PCR. For the negative controls, water was used as template. Standard curves were used to determine mRNA transcript copy number in individual reactions. GAPDH or actin was used to normalize RNA quantities between samples.

Supernatants from IEC stimulated for 24 h were centrifuged (1000 \times g, 10 min, 4°C) to discard the detached cells. The supernatants were collected and frozen at -80°C until determination of cytokine concentrations by ELISA Kits (R&D Systems, Minneapolis, MN, United States), following the manufacturers' instructions.

Isolation and Preparation of Murine Bone Marrow Macrophages

Murine macrophages were isolated as described before (Cho et al., 2012) with some modifications. Briefly, bone marrow-derived monocytes were isolated from tibia and femur harvested from mice. Cells were flushed out with PBS containing 1% FBS then filtered through a 70- μ m cell strainer. The single cell suspension was centrifuged 10 min at 500 \times g then resuspended in macrophage complete media [DMEM/F12 medium supplemented with 10% (v/v) FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 mM L-glutamine, and 10 ng/ml M-CSF]. Cells were seeded on 24-well plates (10⁶ cells per well) and incubated at 37°C in a 5% CO₂ atmosphere. Four days after seeding the cells, an extra 5 ml of fresh macrophage complete medium was added per plate and incubated for an additional 3 days to get adherent cells constituted of approximately 95% macrophages. To obtain bone marrow-derived macrophages (BMDM), the cell supernatant was discarded and the attached cells were washed with 10 ml of sterile PBS. Then, cell stripper non-enzymatic cell dissociation solution (D-PBS containing 1 mM EDTA) was added to each dish and incubated 5 min at 37°C. This solution contains the divalent cation chelator EDTA that gently dislodges adherent cells as an alternative to trypsin. After detachment of macrophages from the plate, an equal volume of cold DMEM/F12-10 medium was added to the wells then cells were centrifuged at 400 \times g for 10 min at 4°C. The cells were counted then used for chemotaxis assay.

In Vitro Chemotaxis Assay

Macrophage chemotaxis was carried out in a Boyden chambers as described before (Cho et al., 2012) with some modifications. Briefly, cell culture inserts (5 μ m pore size) were used to form dual compartments (chambers) in a 24-well culture plate (Corning-Costar, Lowell, MA, United States). Macrophages prepared as described above (10⁶ cells in 0.2 ml of DMEM/F12-5% FBS) were loaded in the upper chamber and their migration was initiated with IEC supernatant prepared as above or with FMLP (10 μ M) as a positive control, added to the bottom chamber. Cell migration was carried out for 24 h at 37°C and 5% CO₂. The migrated macrophages were collected from the bottom chambers and counted with a hemocytometer, as detailed in previous studies (Vereyken et al., 2011; Unver et al., 2015). Basal macrophage migration observed in the absence of IEC

TABLE 1 | qRT-PCR primers.

Gene	Forward primer	Reverse primer	Amplicon (bp)
<i>Vil1</i>	Qiagen	Qiagen	135
<i>Alpi</i>	Qiagen	Qiagen	113
<i>Gapdh</i>	AACTTTGGCATTGTGGAAGG	ACA CAT TGG GGG TAG GAA CA	223
<i>Actb</i>	AGCCATGTACGTAGCCATCC	CTC TCA GCT GTG GTG GTG AA	228
<i>Entpd1</i>	AGC TGC CCC TTA TGG AAG AT	TCA GTC CCA CAG CAA TCA AA	123
<i>Entpd2</i>	TTC CTG GGA TGT CAG GTC TC	GTC TCT GGT GCT TGC CTT TC	132
<i>Entpd3</i>	ACC TGT CCC GTG CTT AAA TG	AGA CAG AGT GAA GCC CCT GA	183
<i>Entpd17</i>	Qiagen	Qiagen	91
<i>Entpd8</i>	CCC TTA TGA ACC CCT GAC CT	AAT CCA ACC ACA GGC TCT TG	292
<i>NtT5e/CD73</i>	CAG GAA ATC CAC CTT CCA AA	AAC CTT CAG GTA GCC CAG GT	128
<i>P2ry1</i>	TCG-TGT-CTC-CAT-TCT-GCT-TG	CGA CAG GGT TTA TGC CAC TT	218
<i>P2ry2</i>	TGA CGA CTC AAG ACG GAC AG	GTC CCC TAC AGC TCC CCT AC	108
<i>P2ry4</i>	AGACGGCCTGATGTGTATC	AGG TTC ACA TGC CCT GTA CC	126
<i>P2ry6</i>	GGT-AGC-GCT-GGA-AGC-TAA-TG	TTT CAA GCG ACT GCT GCT AA	308
<i>P2ry12</i>	GGC-AGC-CTT-GAG-TGT-TCT-TC	ATA ACG TGC TAC CCG ACC TG	130
<i>P2ry13</i>	ATA-GAG-AAC-CGG-GAA-CAG-CA	CAA AAC AAA GCT GAT GCT CG	115
<i>P2ry14</i>	TTT TGT CGT CTG CTT TGT GC	GCA GCC GAG AGT AGC AGA GT	135
<i>P2rx1</i>	CAA CTG TGT GCC CTT CAA TG	GGT ACC ATT CAC CTC CTC CA	114
<i>Pr2x2</i>	GCT GGG CTT CAT TGT AGA GC	CCT GTC CAT GCA CAA TAA CG	281
<i>P2rx3</i>	ATT TCC TCA AAG GGG CTG AT	GTT CTG CAG CCC AAG GAT AA	204
<i>P2rx4</i>	CAC AAC GTG TCT CCT GGC TA	GCC TTT CCA AAC ACG ATG AT	125
<i>P2rx5</i>	CTG TCA CTT CAG CTC CAC CA	TTT GTT GTC CAG ACG GTT GA	196
<i>P2rx6</i>	TCA CCC GCT AAC CCT GTT AC	TAG TCC CGC TGA AGC TTT GT	242
<i>P2rx7</i>	AAT CGG TGT GTT TCC TTT GG	CCG GGT GAC TTT GTT TGT CT	165
<i>Adora 1</i>	GTG ATT TGG GCT GTG AAG GT	AGT AGG TCT GTG GCC CAA TG	142
<i>Adora2a</i>	TCA ACA GCA ACC TGC AGA AC	GGC TGA AGA TGG AAC TCT GC	186
<i>Adora2b</i>	TCT GGC CTT TTG GAG AAG AA	TTT CCG GAA TCA ATT CAA GC	246
<i>Adora3</i>	TGT GGA GGG AGT CTC GTC TT	TCC TTC TGT TCC CCA CAT TC	97

supernatant was <20% of that induced with IEC supernatant and was subtracted from the data presented in the figures.

Statistical Analysis

Results are expressed as mean \pm SEM. The statistical differences between mean values were assessed by two-way ANOVA followed by Bonferroni test using graph-prism software. All results were considered statistically significant at $p < 0.05$ (one symbol), $p < 0.01$ (two symbols), or $p < 0.001$ (three symbols). The symbol (*) was used to compare responses from *P2ry6*^{-/-} IEC with those from WT IEC. The symbol (#) was used to compare responses from stimulated IEC with those from non-stimulated IEC. The symbol (¶) was used to compare responses from poly(I:C)-treated IEC in the presence of inhibitors or antagonist with those from IEC treated with poly(I:C) alone.

RESULTS


P2Y₆ Receptor Is the Major Nucleotide Receptor Expressed in IEC

We first evaluated the expression of P2 receptors in primary IECs isolated from WT colon. P2Y₆ was the nucleotide receptor with the highest mRNA expression in these cells

($13 \times 10^5 \pm 1.7 \times 10^5$ copies/ μ g of cDNA) followed by P2Y₁ ($9.5 \times 10^5 \pm 1.4 \times 10^5$ copies/ μ g of cDNA). There were also lower gene expressions of P2Y₂ ($1.2 \times 10^5 \pm 0.1 \times 10^5$ copies/ μ g of cDNA), P2X₂ ($1.37 \times 10^5 \pm 0.22 \times 10^5$ copies/ μ g cDNA), P2X₄ ($2.2 \times 10^5 \pm 0.11 \times 10^5$ copies/ μ g cDNA), and A_{2A} ($2.1 \times 10^5 \pm 0.5 \times 10^5$ copies/ μ g cDNA) compared to the gene expression of P2Y₆ receptor (Figures 1A,B,E).

Characterization of *P2ry6*^{-/-} IEC

Our main hypothesis is that P2Y₆ receptors regulate functions of IEC related to inflammation. To address this, we used IEC isolated from mice deficient for the expression of P2Y₆ receptor (*P2ry6*^{-/-}). Microscopic observation of IEC and trypan blue staining did not show any apparent differences in the growth and differentiation of WT and *P2ry6*^{-/-} IEC (data not shown). In addition, IEC of both genotypes exhibited similar levels of mRNA of the IEC differentiation markers villin and intestinal alkaline phosphatase (ALPi) before and after differentiation. Before differentiation, the expression of villin and ALPi genes was below $0.04 \times 10^6 \pm 0.002 \times 10^6$ and $0.02 \times 10^6 \pm 0.003 \times 10^6$ copies/ μ g of cDNA, respectively (data not shown), for both WT and *P2ry6*^{-/-} IEC. After differentiation, the expression of these markers was as expected dramatically increased, over $1 \times 10^6 \pm 0.02 \times 10^6$ and




$0.28 \times 10^6 \pm 0.01 \times 10^6$ copies/ μ g of cDNA for villin and ALPi, respectively, for both genotypes as measured by qRT-PCR (Figure 1C).

We then compared the expression of the receptors and enzymes involved in nucleotide signaling in WT and *P2ry6*^{-/-} IEC primary cultures. Aside P2Y₆, we noted similar expression of all P2Y and P2X receptors at the gene level in IEC from both genotypes (Figures 1A,B) as well as of the plasma membrane-bound NTPDases and ecto-5'-nucleotidase (CD73) (Figure 1D). It is noteworthy that these ectonucleotidases not only hydrolyse the agonists of P2 receptors but also generate adenosine which activates P1 receptors. The analysis of P1 receptor expression reveals an important gene expression of the adenosine A_{2A} receptor ($2.1 \times 10^5 \pm 0.4 \times 10^5$ for WT IEC and $2.5 \times 10^5 \pm 0.4 \times 10^5$ for *P2ry6*^{-/-}

IEC) and nearly no expression of the other P1 receptors, in both WT and *P2ry6*^{-/-} IEC, which was in the order of 2×10^5 copies/ μ g of cDNA (Figure 1E). Aside P2Y₆, the minor variations in the expression of the genes tested in Figure 1 between WT and *P2ry6*^{-/-} IEC were all not significantly different.

Together, these data show that *P2ry6*^{-/-} IECs are similar to WT IEC in all aspects analyzed, including gene expression of enzymes and receptors involved in nucleotide signaling, except, obviously, for the gene expression of P2Y₆. We therefore used these cells to investigate the role of P2Y₆ receptor in functions of IEC related to immune responses. More specifically, we investigated the implication of P2Y₆ on IEC stimulated with TLR agonists to explore the contribution of this receptor in responses to PAMP.



CXCL10 Expression and Secretion Are Augmented in *P2ry6*^{-/-} IEC Stimulated by Poly(I:C)

We previously observed that the activation of P2Y₆ was necessary to trigger the secretion of CXCL8 from human monocytes stimulated with TLR-2 ligand (Ben Yebdri et al., 2009). Moreover, P2Y₆ activation increased CXCL8 secretion in the colonic tumor cell line Caco-2/15 (Grbic et al., 2008). Therefore, we hypothesized that in the absence of P2Y₆ in IEC, chemokine secretion would be decreased upon TLR stimulation.

Intestinal epithelial cells express several TLRs at varying levels (Graves et al., 2014). The most important TLR receptors expressed in IEC lines, and which can affect the immune response, are TLR3, TLR4, and TLR5 (Bambou et al., 2004; Graves et al., 2014). We first investigated whether these TLRs induce chemokine expression in primary murine WT IEC and in IEC deficient for the expression of P2Y₆. IECs were stimulated with the TLR agonists poly(I:C) (to activate TLR3), LPS (TLR4), and FLA-ST (TLR5). The expression of the chemokines KC, MIP-2, MCP-1, and CXCL10, known to be expressed by IEC in inflammatory conditions (Yang et al., 1997; Dwinell et al., 2001), was assessed by qRT-PCR.

The stimulation of primary IEC with LPS increased the expression of the four tested chemokines in both WT

and *P2ry6*^{-/-} cells. The expression of KC, MIP-2, MCP-1, and CXCL10 was significantly increased in *P2ry6*^{-/-} IEC ($0.75 \times 10^5 \pm 0.05 \times 10^5$, $0.93 \times 10^5 \pm 0.2 \times 10^5$, $0.95 \times 10^5 \pm 0.1 \times 10^5$, and $1.3 \times 10^5 \pm 0.2 \times 10^5$ copies/μg of cDNA, respectively) when compared to WT IEC treated with LPS ($0.39 \times 10^5 \pm 0.15 \times 10^5$, $p < 0.05$; $0.5 \times 10^5 \pm 0.2 \times 10^5$, $p < 0.05$; $0.55 \times 10^5 \pm 0.18 \times 10^5$, $p < 0.05$, and $0.58 \times 10^5 \pm 0.1 \times 10^5$, $p < 0.01$, copies per μg of cDNA). CXCL10 was the highest chemokine expressed in both WT and *P2ry6*^{-/-} IEC (**Figure 2A**). The TLR3 agonist poly(I:C) also induced the expression of CXCL10 but more strongly [40-fold more than with LPS: 4.5×10^6 and 1.3×10^5 copies/μg of cDNA for poly(I:C) and LPS stimulation, respectively] (**Figures 2A,B**). As for LPS, poly(I:C) induced an increased expression and secretion of CXCL10 more prominently in *P2ry6*^{-/-} IEC than in WT IEC. The gene expression of CXCL10 was $4.5 \times 10^6 \pm 0.5 \times 10^6$ and $2.4 \times 10^6 \pm 0.4 \times 10^6$, $p < 0.001$, copies/μg of cDNA in *P2ry6*^{-/-} IEC and WT IEC, respectively. These data correlated with CXCL10 secretion which were $5.3 \times 10^4 \pm 0.3 \times 10^4$ and $1.8 \times 10^4 \pm 0.2 \times 10^4$ pg/ml, $p < 0.001$, in the supernatant of *P2ry6*^{-/-} IEC and WT IEC, respectively (**Figures 2B–D**). Stimulation with the purified flagellin FLA-ST showed low mRNA expression of the same chemokines (KC, MIP-2, and MCP-1) in both WT and

P2ry6^{-/-} IEC (data not shown). We noted also low mRNA expression and protein secretion of CXCL10 in comparison with LPS and poly(I:C). The gene expression of CXCL10 was $0.08 \times 10^6 \pm 0.001 \times 10^6$ copies/ μ g of cDNA in both *P2ry6*^{-/-} IEC and WT IEC while for CXCL10 secretion was 250 ± 10 pg/ml in the supernatant of both *P2ry6*^{-/-} IEC and WT IEC (Figures 2C,D). These data show that murine primary IEC stimulated with the TLR-3 agonist poly(I:C) expressed high level of CXCL10 and that this production was more pronounced in the absence of P2Y₆ receptor.

Extracellular Nucleotides Are Involved in Poly(I:C)-Induced CXCL10 Release by IEC

In previous studies, we observed that the expression and secretion of the chemokine IL-8 induced by TLR2 and TLR4 activation required the concomitant activation of the nucleotide receptors P2Y₂ and P2Y₆ in human monocytes (Ben Yebdri et al., 2009). Therefore, we were not expecting that the expression of the chemokines tested here would be increased in *P2ry6*^{-/-} IEC as we observed for the four chemokines tested (Figure 2).

We then investigated whether extracellular nucleotides and their receptors played a role in TLR3-induced CXCL10 expression and secretion in both WT and *P2ry6*^{-/-} IEC. As seen in Figure 3A, IEC stimulated with poly(I:C), in the presence of the nucleotide scavenger apyrase or of the general P2 receptor antagonists suramin or RB-2, expressed much less CXCL10 mRNA level in both WT and *P2ry6*^{-/-} IEC. For WT IEC, CXCL10 gene expression was reduced from $2.4 \times 10^6 \pm 0.7 \times 10^6$ to $0.81 \times 10^6 \pm 0.29 \times 10^6$, $p < 0.001$; to $0.88 \times 10^6 \pm 0.14 \times 10^6$, $p < 0.001$ or to $0.9 \times 10^6 \pm 0.15 \times 10^6$, $p < 0.001$, copies/ μ g of cDNA in the presence of apyrase, suramin, or RB-2, respectively. For *P2ry6*^{-/-} IEC, CXCL10 gene expression was reduced from $5.0 \times 10^6 \pm 1.3 \times 10^6$ to $1.62 \times 10^6 \pm 0.002 \times 10^6$, $p < 0.001$; to $2.22 \times 10^6 \pm 0.001 \times 10^6$, $p < 0.001$ or to $1.33 \times 10^6 \pm 0.005 \times 10^6$, $p < 0.001$, copies/ μ g of cDNA in the presence of apyrase, suramin, or RB-2, respectively. Similar data were obtained at the protein level (Figure 3B). These data suggest that nucleotides participate in the regulation of TLR3-induced CXCL10 expression and secretion in IEC.

Supernatants from Poly(I:C)-Stimulated IEC Induce Macrophage Migration *in Vitro*

CXCL10 directs the chemotaxis of lymphocytes and macrophages. This can be observed *in vivo* when these cells migrate to an inflammatory site (Haemmerle et al., 2013; Zhao et al., 2017). We then questioned whether the supernatant of poly(I:C)-stimulated IEC, which contained significant amount of CXCL10 (Figure 3B), induced macrophage migration. Macrophage migration was assessed with a modified Boyden chamber system. The kinetics of cell migration presented in Figure 4A show that the supernatants of *P2ry6*^{-/-} IEC stimulated with poly(I:C) recruited significantly more




FIGURE 3 | The TLR3 ligand poly(I:C) induces CXCL10 expression and secretion from IEC in a nucleotide-dependent manner. IECs were stimulated with poly(I:C) (10 μ g/ml) for 5 h for qRT-PCR, or 24 h for ELISA, in the presence of the P2 blockers suramin (0.1 mM), RB-2 (0.1 mM), or apyrase (2 U/ml) added 20 min before stimulation. The CXCL10 expression (A) and secretion (B) were measured by qRT-PCR and ELISA, respectively. For qRT-PCR, data were normalized to actin mRNA levels. Data presented are the mean \pm SEM of three independent experiments, each with cells pooled from three mice. One symbol $p < 0.05$, two symbols $p < 0.01$, and three symbols $p < 0.001$. *, stimulated IEC from *P2ry6*^{-/-} mice compared with WT; #, poly(I:C) stimulated IEC compared with non-stimulated IEC; and ¶, treated IEC in presence of inhibitors compared with poly(I:C) alone.

macrophages ($5.8 \times 10^5 \pm 0.3 \times 10^5$) than did the supernatants of poly(I:C)-stimulated WT IEC ($2.1 \times 10^5 \pm 0.1 \times 10^5$) (60 vs. 20% of the macrophages added to the upper chamber had migrated to the lower chamber, respectively). This observation is in agreement with the higher concentration of CXCL10 measured in these supernatants. Note that we cannot exclude that other components and chemokines present in supernatants could also be implicated in this macrophage chemotaxis.

Then, we tested whether the inhibition of nucleotide signaling in poly(I:C)-treated IEC by apyrase or general P2 antagonists would diminish the ability of these cell supernatants to attract macrophages to the lower chamber. As shown in Figure 4B, the supernatants of both WT and *P2ry6*^{-/-} IEC stimulated with poly(I:C) in the presence of apyrase, suramin, or RB-2 recruited significantly fewer macrophages than did the supernatants of the cells stimulated in the absence of P2 blockers. Macrophage migration was reduced by about 94, 86, and 75% with supernatants from either WT or *P2ry6*^{-/-} IEC stimulated with poly(I:C) in the presence of suramin, apyrase, or RB-2, respectively. For example, the supernatant of *P2ry6*^{-/-} IEC stimulated with poly(I:C) alone induced the migration of $6.28 \times 10^5 \pm 0.28 \times 10^5$ macrophages which was reduced to $0.42 \times 10^5 \pm 0.57 \times 10^5$, $0.85 \times 10^5 \pm 0.14 \times 10^5$, or $1.42 \times 10^5 \pm 0.14 \times 10^5$ macrophages when the IECs




FIGURE 4 | Supernatants from poly(I:C) stimulated IEC induce macrophage migration in a nucleotide-dependant manner. **(A)** Time course of bone marrow macrophage chemotaxis in Boyden chambers. The supernatant from poly(I:C)-treated WT or *P2ry6*^{-/-} IEC was added to the bottom chamber and 10⁶ BMDMs were applied to the upper chamber and allowed to migrate for 24 h. The migrated macrophages to the bottom chamber were counted with a hemocytometer and the measurements were reported on the Y-axis. Data presented are the mean ± SEM of three independent experiments, each with cells pooled from two mice. **(B)** Different IEC monolayers were preincubated for 20 min with the indicated P2 blockers or apyrase, at the same concentration as in **Figure 3**, prior stimulation with poly(I:C) for 24 h. These supernatants were added to the bottom chamber and macrophage chemotaxis was carried out for 24 h. Data presented are the mean ± SEM of four independent experiments, each with cells pooled from two mice. One symbol *p* < 0.05; three symbols *p* < 0.001. *, stimulated IEC from *P2ry6*^{-/-} mice compared with WT and ¶, treated IEC in the presence of inhibitors compared with poly(I:C) alone.

were stimulated in the presence of suramin, apyrase, or RB-2, respectively. The *p*-values corresponding to these data are significant and are presented in **Figure 4B**.

These data show that supernatant of IEC stimulated with poly(I:C) induced macrophage migration (**Figure 4**) which correlated with the amount of CXCL10 detected in the supernatant of poly(I:C)-stimulated IEC in the presence/absence of P2 blockers (**Figure 3B**).

Several P2 Receptors Are Involved in CXCL10 Expression and Secretion Induced by Poly(I:C) in *P2ry6*^{-/-} IEC


We then tested the involvement of different P2 receptors in the responses described above in both *P2ry6*^{-/-} and WT IEC. We first stimulated these cells with P1 and P2 receptor agonists. The natural ligand ATP, ADP, and UTP increased mRNA expression of CXCL10 in IEC from both, WT and *P2ry6*^{-/-} mice. Again the increase of expression was more prominent in *P2ry6*^{-/-} IEC (**Figure 5A**). The mRNA expression of CXCL10 was

$13.0 \times 10^3 \pm 0.4 \times 10^3$ and $7.35 \times 10^3 \pm 0.58 \times 10^3$, *p* < 0.01, copies/μg of cDNA in *P2ry6*^{-/-} and WT IEC, respectively, when stimulated with ATP. When IECs were stimulated with ADP, it was $14.7 \times 10^3 \pm 0.3 \times 10^3$ and $8.2 \times 10^3 \pm 1.2 \times 10^3$, *p* < 0.01, copies/μg of cDNA for *P2ry6*^{-/-} and WT IEC, respectively. In addition, the specific agonist of P2Y₁ (MRS 2365) and of P2Y₂ (PSB1114) induced CXCL10 mRNA expression in *P2ry6*^{-/-} IEC more prominently than in WT IEC ($16.2 \times 10^3 \pm 1.5 \times 10^3$ vs. $5.9 \times 10^3 \pm 0.9 \times 10^3$, *p* < 0.001, copies/μg of cDNA in the presence of MRS 2365 and $11.8 \times 10^3 \pm 0.3 \times 10^3$ vs. $6.2 \times 10^3 \pm 1.6 \times 10^3$, *p* < 0.01, copies/μg of cDNA in the presence of PSB1114. UDP, the specific agonist of P2Y₆, also induced CXCL10 expression in WT IEC ($8.5 \times 10^3 \pm 1.1 \times 10^3$ copies/μg of cDNA) compared to control IEC ($3.6 \times 10^3 \pm 0.1 \times 10^3$ copies/μg of cDNA) (**Figure 5A**), which suggest that P2Y₆ receptor plays a proinflammatory role in WT IEC. The *p*-value of UDP stimulation is significant and is presented in **Figure 5A**.

As expected, UDP did not induce any response in *P2ry6*^{-/-} IEC confirming the specificity of the assay (**Figure 5A**). In contrast, adenosine failed to induce a response in IEC of both WT and *P2ry6*^{-/-} mice (**Figure 5A**). Finally, **Figure 5B** shows that the CXCL10 protein level was in agreement with the level of expression detected in **Figure 5A**.

The candidate P2Y receptors expressed on IEC P2Y₁, P2Y₂, and P2Y₆ as well as P2X₄ and A_{2A} were tested with specific antagonists. MRS 2500 and MRS 2179 were used to block P2Y₁, AR-C 118925XX to block P2Y₂, MRS 2578 for P2Y₆ receptor, 5-BDBD to prevent P2X₄ activation, and Zm 241385 to block A_{2A} receptor. With the exception of the A_{2A} antagonist, all other selective and specific antagonists tested diminished CXCL10 mRNA expression in IEC upon stimulation with poly(I:C) (**Figure 5C**). For example, for *P2ry6*^{-/-} IEC, CXCL10 mRNA expression decreased from $4.3 \times 10^6 \pm 0.8 \times 10^6$ copies/μg of cDNA in IEC stimulated only with poly(I:C) to $0.45 \times 10^6 \pm 0.08 \times 10^6$, *p* < 0.001; $0.54 \times 10^6 \pm 0.05 \times 10^6$, *p* < 0.001; or $0.18 \times 10^6 \pm 0.01 \times 10^6$, *p* < 0.001, copies/μg of cDNA in the presence of MRS 2179, AR-C, or BDBD, respectively. No significant differences were noted between the responses produced by WT and *P2ry6*^{-/-} IEC in the presence of these antagonists except for P2Y₁ and P2Y₆ antagonists (**Figure 5C**). MRS 2578 did not affect significantly CXCL10 expression in *P2ry6*^{-/-} IEC showing the specificity of the assay. The nucleotide receptor P2X₂ was not tested due to the lack of specific antagonists commercially available. We therefore cannot exclude that this receptor might also have an effect in CXCL10 expression. The A_{2A} antagonist had no effect on CXCL10 expression in either WT or *P2ry6*^{-/-} IEC (**Figure 5C**), which is in agreement with the absence of effect of adenosine on CXCL10 expression (**Figure 5A**). Similar data were obtained for all these antagonists at the protein level (**Figure 5D**).

These data suggest that several nucleotide receptors are involved in poly(I:C) stimulation and that these receptors are more stimulated in the absence of P2Y₆ receptor in *P2ry6*^{-/-} IEC.



FGF2 Signaling Pathway Is Upregulated in P2ry6^{-/-} IEC

Given that there is no difference in the expression of P2 receptors and ectonucleotidases in WT and P2ry6^{-/-} IEC, we questioned whether the “primed” stimulation in P2ry6^{-/-} IEC was specific for nucleotide signaling or if it was also affecting other pathways not dependant on nucleotides. FGF2 stimulation for 6 h is known to induce the secretion of MMP-9 from mouse primary IECs (Song et al., 2015). While the stimulation of WT mouse IEC with FGF2 induced the expected gene expression of MMP-9 ($0.67 \times 10^4 \pm 0.02 \times 10^4$, *p* < 0.05, copies/μg of cDNA), this response was significantly increased in P2ry6^{-/-} IEC ($1.58 \times 10^4 \pm 0.07 \times 10^4$, *p* < 0.01, copies/μg of cDNA) (Figure 6).


DISCUSSION

In this study, we provide evidence that extracellular nucleotides regulate chemokine expression and secretion in primary IEC

from mouse. We found that P2Y₆ was the major nucleotide receptor expressed by primary IEC. We noted also the expression of P2Y₁, P2Y₂, P2X₂, P2X₄, and of the adenosine receptor A_{2A} in IEC. Previous studies also showed the presence of P2Y₆ in Caco2/15 and IEC-6, which are human and rat intestinal cell lines, respectively (Grbic et al., 2008; Nakamura et al., 2013).

We next investigated the role of nucleotides in chemokine secretion by IEC and the implication of P2Y₆ in this function. The activation of P2Y₆ receptor with its specific agonist UDP led to a significant increase of CXCL10 expression and secretion in WT IEC. These data are in line with other studies which showed that P2Y₆ had proinflammatory functions such as the induction of expression and secretion of proinflammatory cytokines and chemokines (Grbic et al., 2008; Ben Yebdri et al., 2009; Hao et al., 2014).

For the following studies, we purified primary IEC from P2ry6^{-/-} mice to verify whether these cells could still release CXCL10 in the absence of P2Y₆. To mimic inflammatory conditions, we used TLR activation as stimuli as mounting evidences suggest that their activation is often, if not always,



associated with the release of nucleotides from affected cells (Yin et al., 2007; Ben Yebdri et al., 2009; Kukulski et al., 2010; Ivison et al., 2011). This process is important as extracellular nucleotides, by activating P2 receptors, have been shown to be necessary for the optimal proinflammatory effects induced by TLR activation. In this study, we found that TLR3 and TLR4 stimulation led to an up-regulation of CXCL10 expression from IEC. The other chemokines tested, KC, MIP-2, and MCP-1, also followed this tendency with an expression level much lower than that of CXCL10. The group of Proost et al. (2003) has reported an increased expression of CXCL10 in fibroblasts and peripheral blood mononuclear cells upon stimulation by TLR3 ligand and IFN- γ .

The TLR3 stimulation with poly(I:C) led to high CXCL10 secretion from IEC of both genotypes (WT and *P2ry6*^{-/-}). The inhibition of this response by general P2 blockers suggests that nucleotides are implicated in these responses. We then further studied the implication of nucleotide signaling in this process. First, the activation of each P2 receptor expressed by IEC, but not P1 receptor, resulted in a significant increase of CXCL10 expression and secretion. CXCL10 expression and secretion induced by a TLR3 agonist were decreased in the presence of the general P2 receptor antagonists suramin and RB-2, and also by the nucleotide scavenger apyrase in both WT and *P2ry6*^{-/-} IEC (Figure 3). In all the experiments above, the level of CXCL10 measured correlated with the level of macrophage chemotaxis reported in Figure 4.

These data suggest that nucleotides play a key role in inducing chemokine expression and secretion by IEC under PAMP stimulation and that several P2 receptors are involved in this response. In agreement with these results, we and others have shown that extracellular nucleotides are implicated in chemokine expression and cell migration. In addition, Kukulski et al. (2010) showed that nucleotides and P2 receptors were required for IL-8 to induce neutrophil migration. In agreement with the above observations, nucleotide hydrolysis by ectoenzymes controlled IL-8 production in the colonic human cell line HT-29 (Bahrami

et al., 2014). In addition to these observations, Ivison et al. (2011) demonstrated that ATP regulated the inflammatory response to flagellin via TLR5 activation in immortalized human IEC.

One surprising observation presented in this paper was that IEC that do not express P2Y₆ induced greater levels of chemokines expression in response to TLR agonists, suggesting that the presence of P2Y₆ negatively regulates the reactivity of other receptors at the surface of IEC. Indeed, we observed that in the absence of P2Y₆, other P2 receptors expressed on IEC such as P2Y₁ and P2Y₂ induced a stronger response than what was measured in WT IEC that express P2Y₆ normally. It is noteworthy to mention that genes of all nucleotide receptors were expressed at similar levels in both WT and *P2ry6*^{-/-} IEC excluding a compensatory mechanism involving a greater expression of another P2 receptor in *P2ry6*^{-/-} IEC. It is noteworthy that the pharmacological inhibition of P2Y₆ activation in WT IEC did not reproduce the stimulatory effect of *p2ry6* gene deletion on the expression and secretion of CXCL10. The P2Y₆ antagonist reduced the poly(I:C)-stimulated expression and secretion of CXCL10. Pharmacological inhibition and gene targeting differ in that, while the MRS 2578 effect is punctual, that of gene deletion is permanent. It is possible that despite the fact that *P2ry6*^{-/-} and WT IEC are equally differentiated, *P2ry6*^{-/-} IEC respond more vigorously to stimulation because P2Y₆ receptors regulate the expression of the component of TLR3 signaling pathway. The examination of this hypothesis is beyond the scope of the present study and will be investigated subsequently.

As the activation of several P2 receptors seemed to be regulated by the presence of P2Y₆, we questioned whether this effect also affected pathways independent of nucleotide signaling. Indeed, FGF2 stimulation induced a greater gene expression of MMP-9 in *P2ry6*^{-/-} IEC than in WT IEC (Figure 6). Altogether, these data suggest that the presence of P2Y₆ regulates the activation of multiple receptors at the surface of IEC in a general manner which may affect the homeostasis of the cells.

Another explanation could be that P2Y₆ triggers not only a signaling pathway which controlled positively chemokine production but also a negative loop to prevent overstimulation of the cells. The interaction between intracellular signaling of P2X and P2Y receptors has already been observed in several cell types (Erb and Weisman, 2012). For example, crosstalk between P2 receptors has previously been reported by Bernier et al. (2013) who showed that P2X₄ activation is controlled by P2Y₆ in microglia possibly through depletion of membrane phosphoinositide resulting from phospholipase C activation by P2Y₆. In a human osteoblast cell line (Jorgensen et al., 1997), Ihara et al. (2005) observed that the activation of P2X₄, P2X₅, and P2X₆ with ATP resulted in IL-6 secretion and that this response was inhibited by the antagonist of P2Y receptors. Activation of human P2Y₁ and P2Y₂ receptors has been shown to potentiate subsequent function-mediated Ca²⁺ signaling which is related to P2X function (Bowler et al., 1999).

As mentioned above, we also observed that CXCL10 expression was decreased in the presence of P2X₄, P2Y₁, and P2Y₂ antagonists in both WT and *P2ry6*^{-/-} IEC. The blockade of an important part of the response by an antagonist of a

single-nucleotide receptor may suggest a complex function of nucleotides in cytokine expression in IEC. The fact that these receptors are coupled to different pathways may partly explain this observation. P2Y₁ is coupled to G_q protein, P2Y₂ is coupled to G₀, P2Y₆ to Gq/11 (Okada et al., 2002; Ando et al., 2010; Harden et al., 2010; Ishida et al., 2013) while P2X₄ is a ligand-gated ion channel (North, 2002). The co-stimulation of different nucleotide receptors to get a function has been well documented in platelets which express P2Y₁, P2Y₁₂, and P2X₁ receptors (Daniel et al., 1998; Jin et al., 1998). The co-stimulation of P2Y₁ and P2Y₁₂ by the same agonist ADP is necessary to induce platelet activation. While P2Y₁ is coupled to phospholipase C, P2Y₁₂ is linked with the inhibition of adenylyl cyclase. If one of these two pathways is blocked, there will be no platelet activation (Jin and Kunapuli, 1998).

It is noteworthy that a cross talk between P2Y receptors and P2X receptor ion channels has also been noted in *Xenopus* oocytes. In these cells, P2X₁ receptor activated by ATP led to a transient inward current that is rapidly desensitized by ATP itself (Rettinger and Schmalzing, 2003). Interestingly, the co-expression and co-activation of either P2Y₁ or P2Y₂ inhibit P2X₁ receptor desensitization. The mechanism of P2Y receptor-mediated inhibition of P2X₁ receptor desensitization does not appear to involve direct phosphorylation of the P2X₁ receptor but does involve protein kinase activity, perhaps mediated by an accessory protein (Jones et al., 2014). Although these mechanisms cannot be shared completely with the data presented here in IEC, it still shows that nucleotide signaling is complex and that several nucleotide receptors may often be needed to control specific effects.

CONCLUSION

The data presented in this study support the view that nucleotide signaling can contribute to leukocyte recruitment to the intestinal epithelium via CXCL10 secretion by IEC. This mechanism involves P2Y₆. The results presented here also show that P2Y₁,

P2Y₂, and P2X₄ also regulate CXCL10 secretion in these cells, especially in the absence of P2Y₆. Indeed, in *P2ry6*^{-/-} IEC, activation of nucleotide receptors induced a stronger expression and secretion of the chemokine CXCL10 when compared to WT IEC. The *P2ry6*^{-/-} IEC also responded more vigorously to a non-nucleotide receptor as demonstrated with FGF2 that induced a stronger expression of MMP9 gene in the *P2ry6*^{-/-} IEC. Therefore, P2Y₆ receptors may not only induce effects such as chemokine release but may also act as a regulator of IEC homeostasis by preventing these cells to over react to various stimuli.

AUTHOR CONTRIBUTIONS

MS conceived the proposal study design, performed all the experiments, analyzed the data, and wrote the first draft of the manuscript. AT helped MS to perform epithelial cell culture and qRT-PCR experiments. JP took care of mice reproduction. BR provided P2Y₆-deficient mice and helped with the analysis of the data and with manuscript writing. JS supervised the study.

FUNDING

This work was supported by grants to JS from the Canadian Institutes of Health Research (CIHR; MOP-102472 and MOP-93683) and from the *Fondation du CHU de Québec*. MS was a recipient of a scholarship from the *Fonds de Recherche du Québec-Santé* (FRQS) and JS of a “Chercheur National” Scholarship award from the FRQS.

ACKNOWLEDGMENTS

We thank Dr. Paul Naccache from the CRCHU de Québec – Université Laval (QC, Canada) for his help with the writing of the manuscript and for helpful discussions.

REFERENCES

- Abbracchio, M. P., Burnstock, G., Boeynaems, J. M., Barnard, E. A., Boyer, J. L., Kennedy, C., et al. (2006). International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol. Rev.* 58, 281–341. doi: 10.1124/pr.58.3.3
- Ando, R. D., Mehesz, B., Gyires, K., Illes, P., and Sperlagh, B. (2010). A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. *Br. J. Pharmacol.* 159, 1106–1117. doi: 10.1111/j.1476-5381.2009.00596.x
- Artis, D. (2008). Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. *Nat. Rev. Immunol.* 8, 411–420. doi: 10.1038/nri2316
- Bahrami, F., Kukulski, F., Lecka, J., Tremblay, A., Pelletier, J., Rockenbach, L., et al. (2014). Purine-metabolizing ectoenzymes control IL-8 production in human colon HT-29 cells. *Mediators Inflamm.* 2014:879895. doi: 10.1155/2014/879895
- Bambou, J. C., Giraud, A., Menard, S., Begue, B., Rakotobe, S., Heyman, M., et al. (2004). *In vitro* and *ex vivo* activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal *Escherichia coli* strain. *J. Biol. Chem.* 279, 42984–42992. doi: 10.1074/jbc.M405410200
- Bar, I., Guns, P. J., Metallo, J., Cammarata, D., Wilkin, F., Boeynaems, J. M., et al. (2008). Knockout mice reveal a role for P2Y₆ receptor in macrophages, endothelial cells, and vascular smooth muscle cells. *Mol. Pharmacol.* 74, 777–784. doi: 10.1124/mol.108.046904
- Ben Yebdri, F., Kukulski, F., Tremblay, A., and Sevigny, J. (2009). Concomitant activation of P2Y(2) and P2Y(6) receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. *Eur. J. Immunol.* 39, 2885–2894. doi: 10.1002/eji.200939347
- Bernier, L. P., Ase, A. R., Boue-Grabot, E., and Seguela, P. (2013). Inhibition of P2X₄ function by P2Y₆ UDP receptors in microglia. *Glia* 61, 2038–2049. doi: 10.1002/glia.22574
- Bondar, C., Araya, R. E., Guzman, L., Rua, E. C., Chopita, N., and Chirido, F. G. (2014). Role of Cxcr3/Cxcl10 axis in immune cell recruitment into the small intestine in celiac disease. *PLoS One* 9:e89068. doi: 10.1371/journal.pone.0089068
- Bowler, W. B., Dixon, C. J., Halleux, C., Maier, R., Bilbe, G., Fraser, W. D., et al. (1999). Signaling in human osteoblasts by extracellular nucleotides. Their weak induction of the c-fos proto-oncogene via Ca²⁺ mobilization is strongly potentiated by a parathyroid hormone/camp-dependent protein kinase pathway independently of mitogen-activated protein kinase. *J. Biol. Chem.* 274, 14315–14324. doi: 10.1074/jbc.274.20.14315

- Braunstein, G. M., Roman, R. M., Clancy, J. P., Kudlow, B. A., Taylor, A. L., Shylonsky, V. G., et al. (2001). Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulation. *J. Biol. Chem.* 276, 6621–6630. doi: 10.1074/jbc.M005893200
- Cho, H. J., Jung, J. I., Lim, D. Y., Kwon, G. T., Her, S., Park, J. H., et al. (2012). Bone marrow-derived, alternatively activated macrophages enhance solid tumor growth and lung metastasis of mammary carcinoma cells in a Balb/C mouse orthotopic model. *Breast Cancer Res.* 14:R81. doi: 10.1186/bcr3195
- Daniel, J. L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J. B., and Kunapuli, S. P. (1998). Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. *J. Biol. Chem.* 273, 2024–2029. doi: 10.1074/jbc.273.4.2024
- Dwinell, M. B., Lugerling, N., Eckmann, L., and Kagnoff, M. F. (2001). Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. *Gastroenterology* 120, 49–59. doi: 10.1053/gast.2001.20914
- Erb, L., and Weisman, G. A. (2012). Coupling of P2Y receptors to G proteins and other signaling pathways. *Wiley Interdiscip. Rev. Membr. Transp. Signal.* 1, 789–803. doi: 10.1002/wmts.62
- Fritz, J. H., Ferrero, R. L., Philpott, D. J., and Girardin, S. E. (2006). Nod-like proteins in immunity, inflammation and disease. *Nat. Immunol.* 7, 1250–1257. doi: 10.1038/ni1412
- Graves, C. L., Harden, S. W., Lapato, M., Nelson, M., Amador, B., Sorenson, H., et al. (2014). A method for high purity intestinal epithelial cell culture from adult human and murine tissues for the investigation of innate immune function. *J. Immunol. Methods* 414, 20–31. doi: 10.1016/j.jim.2014.08.002
- Grbic, D. M., Degagne, E., Langlois, C., Dupuis, A. A., and Gendron, F. P. (2008). Intestinal inflammation increases the expression of the P2Y6 receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP. *J. Immunol.* 180, 2659–2668. doi: 10.1002/jimmunol.180.4.2659
- Haemmerle, M., Keller, T., Egger, G., Schachner, H., Steiner, C. W., Stokic, D., et al. (2013). Enhanced lymph vessel density, remodeling, and inflammation are reflected by gene expression signatures in dermal lymphatic endothelial cells in type 2 diabetes. *Diabetes Metab. Res. Rev.* 62, 2509–2529. doi: 10.2337/db12-0844
- Hao, Y., Liang, J. F., Chow, A. W., Cheung, W. T., and Ko, W. H. (2014). P2Y6 receptor-mediated proinflammatory signaling in human bronchial epithelia. *PLoS One* 9:e106235. doi: 10.1371/journal.pone.0106235
- Harden, T. K., Sesma, J. I., Fricks, I. P., and Lazarowski, E. R. (2010). Signalling and pharmacological properties of the P2Y receptor. *Acta Physiol.* 199, 149–160. doi: 10.1111/j.1748-1716.2010.02116.x
- Hazama, A., Shimizu, T., Ando-Akatsuka, Y., Hayashi, S., Tanaka, S., Maeno, E., et al. (1999). Swelling-induced, CFTR-independent ATP release from a human epithelial cell line: lack of correlation with volume-sensitive Cl⁻ channels. *J. Gen. Physiol.* 114, 525–533. doi: 10.1085/jgp.114.4.525
- Ihara, H., Hirukawa, K., Goto, S., and Togari, A. (2005). ATP-stimulated interleukin-6 synthesis through P2Y receptors on human osteoblasts. *Biochem. Biophys. Res. Commun.* 326, 329–334. doi: 10.1016/j.bbrc.2004.11.037
- Ishida, K., Matsumoto, T., Taguchi, K., Kamata, K., and Kobayashi, T. (2013). Mechanisms underlying reduced P2Y(1)-receptor-mediated relaxation in superior mesenteric arteries from long-term streptozotocin-induced diabetic rats. *Acta Physiol.* 207, 130–141. doi: 10.1111/j.1748-1716.2012.02469.x
- Iverson, S. M., Himmel, M. E., Mayer, M., Yao, Y., Kifayet, A., Levings, M. K., et al. (2011). The stress signal extracellular ATP modulates anti-flagellin immune responses in intestinal epithelial cells. *Inflamm. Bowel Dis.* 17, 319–333. doi: 10.1002/ibd.21428
- Jin, J., Daniel, J. L., and Kunapuli, S. P. (1998). Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. *J. Biol. Chem.* 273, 2030–2034. doi: 10.1074/jbc.273.4.2030
- Jin, J., and Kunapuli, S. P. (1998). Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. *Proc. Natl. Acad. Sci. U.S.A.* 95, 8070–8074. doi: 10.1073/pnas.95.14.8070
- Jones, S., Evans, R. J., and Mahaut-Smith, M. P. (2014). Ca²⁺ influx through P2X1 receptors amplifies P2Y1 receptor-evoked Ca²⁺ signaling and ADP-evoked platelet aggregation. *Mol. Pharmacol.* 86, 243–251. doi: 10.1124/mol.114.092528
- Jorgensen, N. R., Geist, S. T., Civitelli, R., and Steinberg, T. H. (1997). ATP- and gap junction-dependent intercellular calcium signaling in osteoblastic cells. *J. Cell Biol.* 139, 497–506. doi: 10.1083/jcb.139.2.497
- Jung, H. C., Eckmann, L., Yang, S. K., Panja, A., Fierer, J., Morzycka-Wroblewska, E., et al. (1995). A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. *J. Clin. Invest.* 95, 55–65. doi: 10.1172/JCI117676
- Kauffenstein, G., Furstenuau, C. R., D'orleans-Juste, P., and Sevigny, J. (2010). The ecto-nucleotidase Ntpdase1 differentially regulates P2Y1 and P2Y2 receptor-dependent vasorelaxation. *Br. J. Pharmacol.* 159, 576–585. doi: 10.1111/j.1476-5381.2009.00566.x
- Kim, B., Jeong, H. K., Kim, J. H., Lee, S. Y., Jou, I., and Joe, E. H. (2011). Uridine 5'-diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y6 receptor. *J. Immunol.* 186, 3701–3709. doi: 10.4049/jimmunol.1000212
- Kukulski, F., Ben Yebdri, F., Bahrami, F., Fausther, M., Tremblay, A., and Sevigny, J. (2010). Endothelial P2Y2 receptor regulates LPS-induced neutrophil transendothelial migration in vitro. *Mol. Immunol.* 47, 991–999. doi: 10.1016/j.molimm.2009.11.020
- Kukulski, F., Ben Yebdri, F., Lefebvre, J., Warny, M., Tessier, P. A., and Sevigny, J. (2007). Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo. *J. Leukoc. Biol.* 81, 1269–1275. doi: 10.1189/jlb.120.6758
- Kukulski, F., Levesque, S. A., and Sevigny, J. (2011). Impact of ectoenzymes on p2 and p1 receptor signaling. *Adv. Pharmacol.* 61, 263–299. doi: 10.1016/B978-0-12-385526-8.00009-6
- Laragione, T., Brenner, M., Sherry, B., and Gulko, P. S. (2011). Cxcl10 and its receptor Cxcr3 regulate synovial fibroblast invasion in rheumatoid arthritis. *Arthritis Rheum.* 63, 3274–3283. doi: 10.1002/art.30573
- Lazarowski, E. R., Boucher, R. C., and Harden, T. K. (2003). Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. *Mol. Pharmacol.* 64, 785–795. doi: 10.1124/mol.64.4.785
- Medzhitov, R. (2007). TLR-mediated innate immune recognition. *Semin. Immunol.* 19, 1–2. doi: 10.1016/j.simm.2007.02.001
- Moon, C., Vandussen, K. L., Miyoshi, H., and Stappenbeck, T. S. (2014). Development of a primary mouse intestinal epithelial cell monolayer culture system to evaluate factors that modulate IgA transcytosis. *Mucosal Immunol.* 7, 818–828. doi: 10.1038/mi.2013.98
- Nakamura, T., Murata, T., Hori, M., and Ozaki, H. (2013). UDP induces intestinal epithelial migration via the P2Y6 receptor. *Br. J. Pharmacol.* 170, 883–892. doi: 10.1111/bph.12334
- North, R. A. (2002). Molecular physiology of P2X receptors. *Physiol. Rev.* 82, 1013–1067. doi: 10.1152/physrev.00015.2002
- Okada, M., Nakagawa, T., Minami, M., and Satoh, M. (2002). Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model rats. *J. Pharmacol. Exp. Ther.* 303, 66–73. doi: 10.1124/jpet.102.036079
- Ostvik, A. E., Granlund, A. V., Bugge, M., Nilsen, N. J., Torp, S. H., Waldum, H. L., et al. (2013). Enhanced expression of Cxcl10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation. *Inflamm. Bowel Dis.* 19, 265–274. doi: 10.1002/ibd.23034
- Petrovic-Djergovic, D., Popovic, M., Chittiprol, S., Cortado, H., Ransom, R. F., and Partida-Sanchez, S. (2015). Cxcl10 induces the recruitment of monocyte-derived macrophages into kidney, which aggravate puromycin aminonucleoside nephrosis. *Clin. Exp. Immunol.* 180, 305–315. doi: 10.1111/cei.12579
- Proost, P., Vynckier, A. K., Mahieu, F., Put, W., Grillet, B., Struyf, S., et al. (2003). Microbial Toll-like receptor ligands differentially regulate Cxcl10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. *Eur. J. Immunol.* 33, 3146–3153. doi: 10.1002/eji.200324136
- Qureshi, S., and Medzhitov, R. (2003). Toll-like receptors and their role in experimental models of microbial infection. *Genes Immun.* 4, 87–94. doi: 10.1038/sj.gene.6363937
- Rettinger, J., and Schmalzing, G. (2003). Activation and desensitization of the recombinant P2X1 receptor at nanomolar ATP concentrations. *J. Gen. Physiol.* 121, 451–461. doi: 10.1085/jgp.200208730

- Singh, U. P., Singh, N. P., Murphy, E. A., Price, R. L., Fayad, R., Nagarkatti, M., et al. (2016). Chemokine and cytokine levels in inflammatory bowel disease patients. *Cytokine* 77, 44–49. doi: 10.1016/j.cyto.2015.10.008
- Song, X., Dai, D., He, X., Zhu, S., Yao, Y., Gao, H., et al. (2015). Growth factor FGF2 cooperates with interleukin-17 to repair intestinal epithelial damage. *Immunity* 43, 488–501. doi: 10.1016/j.immuni.2015.06.024
- Suzuki, K., Kawauchi, Y., Palaniyandi, S. S., Veeraveedu, P. T., Fujii, M., Yamagiwa, S., et al. (2007). Blockade of interferon-gamma-inducible protein-10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells. *Pathol. Int.* 57, 413–420. doi: 10.1111/j.1440-1827.2007.02117.x
- Tomita, K., Freeman, B. L., Bronk, S. F., Lebrasseur, N. K., White, T. A., Hirsova, P., et al. (2016). Cxcl10 mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. *Sci. Rep.* 6:28786. doi: 10.1038/srep28786
- Ugucioni, M., Gionchetti, P., Robbiani, D. F., Rizzello, F., Peruzzo, S., Campieri, M., et al. (1999). Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. *Am. J. Pathol.* 155, 331–336. doi: 10.1016/S0002-9440(10)65128-0
- Unver, N., Esendagli, G., Yilmaz, G., and Guc, D. (2015). Cxcl7-induced macrophage infiltration in lung tumor is independent of Cxcr2 expression: Cxcl7-induced macrophage chemotaxis in LLC tumors. *Cytokine* 75, 330–337. doi: 10.1016/j.cyto.2015.07.018
- Vereyken, E. J., Heijnen, P. D., Baron, W., De Vries, E. H., Dijkstra, C. D., and Teunissen, C. E. (2011). Classically and alternatively activated bone marrow derived macrophages differ in cytoskeletal functions and migration towards specific CNS cell types. *J. Neuroinflammation* 8:58. doi: 10.1186/1742-2094-8-58
- Vitiello, L., Gorini, S., Rosano, G., and La Sala, A. (2012). Immunoregulation through extracellular nucleotides. *Blood* 120, 511–518. doi: 10.1182/blood-2012-01-406496
- Warny, M., Aboudola, S., Robson, S. C., Sevigny, J., Communi, D., Soltoff, S. P., et al. (2001). P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. *J. Biol. Chem.* 276, 26051–26056. doi: 10.1074/jbc.M102568200
- Yang, S. K., Eckmann, L., Panja, A., and Kagnoff, M. F. (1997). Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. *Gastroenterology* 113, 1214–1223. doi: 10.1053/gast.1997.v113.pm9322516
- Yin, J., Xu, K., Zhang, J., Kumar, A., and Yu, F. S. (2007). Wound-induced ATP release and EGF receptor activation in epithelial cells. *J. Cell Sci.* 120, 815–825. doi: 10.1242/jcs.03389
- Zhao, Q., Kim, T., Pang, J., Sun, W., Yang, X., Wang, J., et al. (2017). A novel function of cxcl10 in mediating monocyte production of proinflammatory cytokines. *J. Leukoc. Biol.* 102, 1271–1280. doi: 10.1189/jlb.5A0717-302

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Salem, Tremblay, Pelletier, Robaye and Sévigny. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.